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Abstract: 
Sickle cell disease-related organ injuries cannot be prevented despite hydroxyurea use, infection prophylaxis, and supportive 
therapies. As a consequence, disease-related mortality reaches 14% in adolescents and young adults. Hematopoietic stem cell 
transplantation is a unique curative therapeutic approach for sickle cell disease. Myeloablative allogeneic hematopoietic stem 
cell transplantation is curative for children with sickle cell disease. Current data indicate that long-term disease-free survival is 
about 90% and overall survival about 95% after transplantation. However, it is toxic in adults due to organ injuries. In addition, 
this curative treatment approach has several limitations, such as difficulties to find donors, transplant-related mortality, graft 
loss, graft-versus-host disease (GVHD), and infertility. Engraftment effectivity and toxicity for transplantations performed with 
nonmyeloablative reduced-intensity regimens in adults are being investigated in phase 1/2 trials at many centers. Preliminary 
data indicate that GVHD could be prevented with transplantations performed using reduced-intensity regimens. It is necessary 
to develop novel regimens to prevent graft loss and reduce the risk of GVHD.
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Özet:
Günümüzde hidroksiüre kullanımı, enfeksiyon proflaksisi ve destek tedavileriyle ilgili gelişmelere rağmen orak hücre 
hastalığına bağlı organ hasarları engellenememekte, adölesan ve genç yetişkinlerde hastalık ilişkili mortalite %14’lere kadar 
ulaşmaktadır. Hematopoietik kök hücre transplantasyonu, orak hücre hastalığı tedavisinde tek küratif tedavi yaklaşımıdır. 
Myeloablatif allojenik hematopietik kök hücre transplantasyonu orak hücre hastalığı olan çocuklar için küratiftir. Güncel 
veriler çocuklarda transplant sonrası uzun dönem hastalıksız yaşam oranının %90 ve toplam yaşam oranının %95 civarında 
olduğunu göstermektedir. Erişkinde hazırlama rejimleri organ hasarları nedeniyle fazla toksiktir. Ayrıca bu küratif tedavi 
yaklaşımının donör bulma güçlüğü, transplant ilişkili mortalite, graft kaybı, graft-versus-host hastalığı (GVHH), infertilite 
gibi nedenlerle sınırlamaları vardır. Güncel olarak erişkinde toksisitesi azaltılmış hazırlama rejimleri (myeloablatif olmayan 
indirgenmiş yoğunluklu) ile yapılan transplantların faz 1/2 çalışmalar ile graft yerleşmesi üzerine etkinliği ve toksisitesi birçok 
merkez tarafından araştırılmaktadır. Ön veriler, toksisitesi azaltılmış rejimler ile yapılan nakillerde başarılı olarak GVHH’nin 
engellenebildiğini göstermiştir. Bununla birlikte yüksek graft kaybı riski devam etmektedir. Bu yüzden orak hücre hastalarında 
uygulanabilen, GVHH riski azaltılmış ve graft kaybının engellenebildiği yeni rejimlerin geliştirilmesi gereklidir.
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Introduction
Disease Overview
Sickle cell disease (SCD) is a homozygous hemoglobin 
S disease characterized by chronic anemia and tissue injury. 
Annually, approximately 300,000 babies are born with SCD 
worldwide. One in every 600 African-Americans in the United 
States is affected by the disease [1]. Central to the pathogenesis 
of SCD is a mutation leading to abnormal polymerization of 
hemoglobin and formation of the characteristic sickle shape 
as a response to deoxygenation [2,3]. Microvascular ischemia 
and endothelial activation are responsible for tissue injury. 
To date, drug therapy for SCD is limited to fetal hemoglobin-
stimulating medicines and nonnarcotic and narcotic agents. 
Use of antisickling agents is not standard, while experience 
with gene therapy is insufficient. Allogeneic stem cell 
transplantation is a curative intervention, but it carries a high 
risk of morbidity and mortality. The development of transplant 
techniques seems to give better results. In this review, we aim 
to highlight questions related to transplantation procedures 
and to discuss our proposals. 
Current Reasons for Transplantation
Current reasons for accepting the risk of transplantation 
are summarized below. First, the clinical manifestations and 
complications are dramatic in SCD patients. Second, despite 
their high costs, no treatment protocol is for protecting from 
complications. Third, transplantation techniques and patient 
care have evolved over time. 
Manifestations and Complications of Sickle Cell Disease
SCD is characterized by hemolytic anemia, painful 
vaso-occlusive crisis, stroke, avascular necrosis, pulmonary 
hypertension, susceptibility to infections, renal failure, and 
thrombosis. Consequently, life expectancy is decreased. 
Neurologic complications develop in 27% of children with 
SCD and acute chest syndrome in 25% [4,5]. These tissue 
injuries significantly influence quality of life in most patients.
Frontline Treatment Options and Disease Course
The current, treatment modalities for SCD include fluid 
replacement, pain control using opioids and analgesics during 
vaso-occlusive crises, oral hydroxyurea, transfusion, and 
chelating therapy. Hydroxyurea is effective for reducing the 
frequency of painful crises and recommended for adults with 
recurrent episodes of acute chest syndrome [6,7]. Maintaining 
sickle hemoglobin levels of less than 30% by transfusion 
may prevent or control adverse events associated with SCD 
[8,9]. However, these complications may develop despite 
hydroxyurea use and regular blood transfusions [4,5]. Painful 
ischemic episodes lead to irreversible sequelae by affecting 
bones, joints, muscles, and the heart, intestines, kidneys, and 
eyes. Mean survival is 40 years in developed countries despite 
advanced supportive care [10]. At our institute, the mean age 
of patients who died within the last 10 years was 30 years 
(unpublished data).
Cost
The disease also has high treatment costs. A study using 
data from the Florida Medicaid program showed a healthcare 
cost per patient per month of $1389, with significant increases 
in SCD-related costs from $892 in the 0-9-years cohort to 
$2562 in the 50-64-years cohort [11]. The cost of chronic 
transfusions and chelating therapy alone is $40,000 per 
patient per year in the United States [12,13].
Allogeneic Stem Cell Transplantation
Hematopoietic stem cell transplantation (HSCT) is a unique 
curative therapeutic approach in SCD [14,15,16]. HSCT may 
improve central nervous system (CNS), pulmonary system, 
and pain symptoms by stabilizing organ functions [17,18]. 
Overall survival was reported to be 90%, disease-free survival 
82%-100%, graft rejection 8%-18%, and transplant-related 
mortality (TRM) 4%-14% in transplantations performed 
mainly with myeloablative conditioning regimens with fully 
HLA-matched donors in various countries [15,19,20,21,22]. 
However, this curative treatment approach has some 
limitations, such as difficulties to find donors, TRM, graft loss, 
graft-versus-host disease (GVHD), and infertility.
Indications for Transplantation
Problem: Although HSCT has a curative potential in this 
nonmalignant disease, it is difficult to determine in which patients 
the risk of the procedure is acceptable.
Current HSCT indications are summarized in Table 1.
Extreme variation in the clinical phenotypes of SCD patients 
makes it difficult to predict the course of the transplantation 
procedure. However, certain clinical and laboratory factors may 
predict transplant-associated problems. These factors are renal 
insufficiency, age >16 years, hepatic function abnormalities, and 
high inflammation [5,17,22,23,24]. In addition, alloantibodies 
against erythrocytes and HLA antigens and excess iron load 
develop due to transfusions in the vast majority of patients [25]. 
Transcranial Doppler ultrasound was shown to be effective 
for determining the severity of the disease and stroke risk in 
children. Starting blood transfusion therapy early reduces the 
risk [26]. Unfortunately, no reliable method is available to 
predict which patients would develop stroke.
On the other hand, hydroxyurea reduces the frequency 
and severity of vaso-occlusive crises and acute chest syndrome 
crises. However, organ injuries continue to occur despite 
hydroxyurea and current supportive therapies, and mean 
survival of patients is about 40 years [4,27]. The presence 
of organ injuries is associated with increased mortality and 
morbidity.
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Proposed solution: Adult SCD patients have generally been 
excluded from myeloablative bone marrow transplantation 
trials because of anticipated excess morbidity and mortality 
resulting from accumulated disease-related end-organ 
damage. Rational thought requires applying a curative 
treatment (i.e. HSCT) in the early period before organ injuries 
that significantly reduce the life span develop.
Donor
Problem: The likelihood of finding an HLA-identical sibling 
donor is low for SCD patients.
In the United States, the estimated number of homozygous 
SCD patients is around 70,000-100,000 and the overall number 
of patients who have indications for transplantation is around 
5000-7000. A total of 1200 transplantations for SCD were 
reported in 1986-2013 according to Center for International 
Blood and Marrow Transplant Research (CIBMTR) and 
European Society for Blood and Marrow Transplantation 
(EBMT) records. These rates may be stated to be much lower 
than needed and expected (Table 2). In a study by Hsieh et 
al., 24 out of 112 adult patients (21%) had suitable donors 
for transplantation. However, the procedure could only be 
performed in 10 patients (8.9%) [28].
The vast majority of healthy HLA-identical sibling donors 
are hemoglobin S carriers. Although there is evidence that 
peripheral stem cell mobilization with G-CSF is safe in 
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Table 1. Indications for hematopoietic stem cell transplantation.
Indications for HSCT (patients ≤16 years)  Indications for HSCT (patients ≥16 years)
Stroke or transient CNS event Stroke
Silent stroke with cognitive impairment MRI imaging changes of brain parenchymal damage
MRI imaging changes of brain parenchymal damage MRI angiogram evidence of cerebrovascular disease
MRI angiogram evidence of cerebrovascular disease ACS requiring exchange transfusion or hospitalization
Recurrent vaso-occlusive pain crises (≥2 per year for 
the last 2 years), requiring hospitalizations
Recurrent vaso-occlusive pain crises (≥2 per year for the last 2 
years), requiring hospitalizations
ACS requiring recurrent hospitalizations Osteonecrosis of multiple joints
Osteonecrosis of multiple joints Stage I or II sickle lung disease
ACS requiring recurrent hospitalizations Pulmonary hypertension
Elevated TCD Sickle hepatopathy (including iron overload)
Red cell alloimmunization (≥2 antibodies) Sickle-related renal insufficiency (CR ≥1.5 times the upper limit of 
normal or biopsy-proven )
 Elevated TRV of ≥2.6 m/s
 Sickle retinopathy
 Red cell alloimmunization (≥2 antibodies)
 Recurrent priapism
 
HSCT: Hematopoietic stem cell transplantation, ACS: acute chest syndrome, MRI: magnetic resonance imaging, TCD: transcranial doppler, TRV: tricuspid regurgitant 
velocity.
Table 2. Transplantations for sickle cell disease by donor 
type and overall survival according to European Society for 
Blood and Marrow Transplantation-Eurocord and Center 
for International Blood and Marrow Transplant Research.
 EBMT-Eurocord CIBMTR 
Transplantations for 
SCD
  
Total 611 627
Type of donor   
HLA-identical 487 430
Cord blood, related 
and unrelated
73 71
Haploidentical donor 34 61
Other unrelated 
donor
17 65
SCD: Sickle cell disease, CIBMTR: Center for International Blood and Marrow Trans-
plant Research, EBMT: European Society for Blood and Marrow Transplantation.
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hemoglobin S carrier donors, it should be remembered that 
G-CSF administration could lead to severe and sometimes 
fatal sickle cell crisis in carrier donors [29,30,31]. Multiorgan 
failure was reported in 2 from 11 cases and in 1 case it was 
fatal. Four people who developed complications required 
hospitalization. Multiorgan failure and sickle cell crisis were 
reported to be independent of leukocyte count and G-CSF 
dose (2.5-10 μg/kg/day), but they seem to be associated 
with hemoglobin S concentration [29,30,31]. Erythrocyte 
exchange or erythrocyte transfusion may be required to 
reduce the level to <30% prior to mobilization. However, there 
are no data for plerixafor mobilization in hemoglobin S carrier 
donors. Theoretically, plerixafor might be safer than G-CSF 
for mobilization as it does not trigger hyperleukocytosis and 
bone marrow hyperplasia [32].
Severe pain may begin 1 h after apheresis without 
mobilization due to transfusion of the erythrocytes, which 
wait hypoxically in the pulley of the apheresis device. Bone 
marrow harvesting is safe under local or general anesthesia 
with careful perioperative management. However, the 
difficulty in collecting an adequate amount of stem cells 
for an adult should be remembered. On the other hand, no 
technical difficulties for cryopreservation were reported in 
sickle cell carriers who could easily tolerate the procedure 
[28,29,30,31,33].
Proposed solution: Due to the abovementioned problems, 
donors who are not carriers should preferably be selected 
in the interest of donor safety. The hemoglobin S level 
should be decreased to <30% if the donor is a carrier. Bone 
marrow should be harvested, if possible. Plerixafor should be 
preferred for mobilization of carrier donors and the rinse-back 
procedure should be avoided in apheresis procedures.
Overall, less than 25% of SCD patients have a healthy HLA-
identical relative donor. HLA-identical unrelated donors can 
be found for only a small proportion of patients [34]. A trial 
of unrelated cord blood transplantation (CBT) was terminated 
early due to high risks of rejection and GVHD [35]. On the other 
hand, almost all patients have a haploidentical relative donor. 
Bolanos-Meade et al. showed that no patients who underwent 
mismatched transplantation using cyclophosphamide 
developed GVHD or severe immunodeficiency complications 
[36]. However, the risk of graft rejection is high in these 
patients as they are immunocompetent and have proliferative 
bone marrow. Conditioning regimens are designed to give a 
low GVHD risk. This problem may be overcome by further 
developing conditioning regimens (see conditioning regimens 
below).
Stem Cell Source
Problem: The ideal stem cell source is not known.
Bone marrow: Bone marrow should be the preferred as 
the stem cell source due to the low risk of chronic GVHD 
(cGVHD). However, HLA-matched donors can be found for 
only a small proportion of patients. G-CSF-mobilized marrow 
has been used in the haploidentical (family donor) setting. 
The use of G-CSF-primed bone marrow grafts to reduce graft 
loss has been reported [36]. The difficulty in collecting a 
sufficient amount of stem cells in adults should be considered. 
In addition, there is evidence that donors of African origin 
have lower blood counts and reduced numbers of marrow 
progenitor cells [37].
Haploidentical bone marrow transplantation with 
posttransplant cyclophosphamide has been applied in patients 
with hematological malignancies for several years. The Johns 
Hopkins Group reported that this approach is a feasible and 
effective treatment with acceptable toxicity [38]. Evidence 
on the potential use of bone marrow from haploidentical 
related donors has increased in patients with SCD. Bolanos-
Meade et al. reported promising results with haploidentical 
nonmyeloablative bone marrow transplantation. They 
reported durable engraftment and acceptable toxicity with no 
morbidity and mortality in their series [36].
Peripheral stem cells: They can easily be collected 
without general anesthesia in the outpatient setting. Their 
application is less traumatic and has advantages such as less 
need for transfusion, faster engraftment, less need for platelet 
suspension, and shorter hospital stays. Although peripheral 
stem cell products with a 10-fold higher T-cell count increase 
the risk of cGVHD, their engraftment-facilitating effect should 
be considered.
Cord blood: This stem cell source has some limitations, 
such as difficulty to find an HLA-identical donor, GVHD, and 
graft rejection, despite data showing successful treatment 
of patients by CBT. A study from the Eurocord Cooperative 
Group, analyzing the outcome in 44 patients who had SCD 
or thalassemia major and were treated by CBT with a sibling 
donor, reported no fatal transplantation-related complications, 
suggesting that CBT with a related donor is a safe treatment 
for hemoglobin disorders [38]. However, CBT with matched 
unrelated donors will likely not be applicable to sufficient 
numbers of SCD patients because of a lack of suitable donors 
in national and worldwide registries. CBT with mismatched 
unrelated donors, although more feasible for pediatric patients 
based on the availability of 4/6 HLA-matched cord blood 
units, appears to be associated with a greater risk of graft 
rejection and GVHD on the basis of the limited data available 
[39]. Drawbacks such as increased rates of graft rejection, 
the fixed cell dose, delayed immune reconstitution, and TRM 
have deterred unrelated cord transplantation efforts [39]. 
Furthermore, CBT for adults will be limited by the necessary 
total nucleated cell count per kilogram of body weight for 
engraftment to occur and the difficulty in achieving this goal 
in adult patients. Double umbilical cord blood allogeneic 
Özdoğu H, et al: Hematopoietic Stem Cell Transplantation in Adult Sickle Cell Disease
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transplantation with reduced-intensity conditioning is 
increasingly used in adults lacking a suitable related or 
unrelated donor [40]. However, the studies of expanded and 
double cord blood are inadequate.
Proposed solution: Current data indicate that peripheral 
stem cells mobilized with G-CSF could be a suitable stem 
cell source for patients with SCD [32]. If the donor is a 
carrier, decreasing hemoglobin S level below 30% of total 
hemoglobin concentration might be recommended for a safer 
mobilization process and apheresis procedure. Hematopoietic 
and lymphoid reconstruction is rapidly achieved through 
replacement of T cells by donor peripheral stem cells. Bone 
marrow from haploidentical donors might be an alternative 
to matched related or unrelated donors, but this needs more 
research [40]. Mesenchymal stem cell co-infusion may be 
considered to prevent GVHD and/or cGVHD and graft loss 
[41,42,43].
Conditioning Regimens
Problem: Engraftment efficacy and toxicity for transplantation 
performed with nonmyeloablative reduced-intensity conditioning 
regimens are currently being investigated in phase I/II trials 
at many centers. Preliminary data indicate that GVHD could 
be prevented by nonmyeloablative reduced-intensity regimens. 
However, the risk of graft loss remains high.
Allogeneic bone marrow transplantation performed with 
an HLA-matched donor using a myeloablative-conditioning 
regimen can cure symptomatic children with SCD. The cure 
rate was reported to be 85%, the rate of TRM 7%, and the 
rate of graft rejection 8% in studies including approximately 
200 patients [16,38,44]. The results were improved by adding 
ATG to the conditioning regimen, which gave a cure rate of 
95% (Table 3) [45]. Adult SCD patients have to be excluded 
from most studies using ablative regimens due to end-organ 
injury-related morbidity and mortality in most patients, 
despite positive results in childhood.
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Table 3. Myeloablative hematopoietic stem cell transplantation with matched related donors.
Reference Transplantation 
Regimen
Number of 
Patients
(age range, 
years)
Alive 
without
SCD,
n (%)
Acute 
GVHD
Chronic 
GVHD
Death 
(cause)
Comments
Vermylen 
et al. [15], 
1998
Bu 16 mg/kg, Cy
200 mg/kg ± TLI or 
ATG, CSA
50 (0.3-11) 45 (90) 10 (Gr 1); 
9 (Gr 2);
1 (Gr 
3-4)
7 limited,
3 extensive
2 (acute 
GVHD with 
CMV and
Aspergillus; 
sudden 
death)
At 5 years after 
HSCT, 6 had 
mixed
chimerism (3: 
>90%, 3: 50%-
70%)
Walters et 
al. [14,20], 
1996, 2001
Bu 14 mg/kg, Cy
200 mg/kg, ATG or
alemtuzumab, 
MTX, CSA
59 (3-16) 50 (85 11 (acute 
or
chronic 
GVHD)
3, all 
GVHD
 At 3.5 years after 
HSCT, 13 had 
mixed
chimerism (8 
with 90%-99%, 
5 with
11%-74%)
Brachet et 
al. [19], 
2004
Bu 14-16 mg/kg,
Cy 200 mg/kg ± 
ATG, MTX, CSA
24 (2-14) 19 (79) 3 (Gr 2); 
3 (Gr 3)
7 limited 1 
(unknown)
At 8.7 years after 
HSCT, 1 had 
mixed
chimerism
Bernaudin 
et al. [16], 
2007
Bu 16 mg/kg, Cy
200 mg/kg ± ATG,
CSA ± MTX
87 (2-22) 80 (92) 10 (Gr 2); 
5 (Gr 3);
2 (Gr 4)
9 limited,
2 extensive
6 (sepsis, 
CNS 
hemorrhage,
and GVHD 
in 4)
At 6 years after 
HSCT, 25%-40% 
had mixed
chimerism  
(5%-95%)
 
ATG: Antithymocyte globulin, Bu: busulfan, CSA: cyclosporine A, Cy: cyclophosphamide, Gr: grade, MTX: methotrexate, SCD: sickle cell disease, GVHD: graft-versus-host 
disease.
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In the past, nonmyeloablative bone marrow 
transplantation strategies developed to cure SCD patients 
with organ dysfunction gave disappointing results [46,47]. 
Transplantations done with nonmyeloablative regimens 
were not as successful as myeloablative transplantations. The 
main reasons for this included the recipient’s not being fully 
immunocompetent, having proliferative bone marrow, and 
lack of a GVHD effect. Recently, inconsistently with previous 
studies, several small patient series have shown promising 
results [28,36,48,49]. Therefore, HSCT following a reduced-
intensity conditioning nonmyeloablative regimen emerged as 
a potential treatment option (Table 4).
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Table 4. Hematopoietic stem cell transplantation from matched related donors with nonmyeloablative conditioning.
Reference Transplant 
Regimen
Number of 
Patients  (age 
range, years)
Alive 
without 
SCD
Acute 
GVHD
Chron-
ic  GVHD
Death
(cause)
Comments
Bolanos-
Meade et al. 
[36], 2012
TBI 200 cGy, 
Flu 150 mg/kg, 
Cy 14.5 mg/
kg, ATG 4.5 
mg/kg, post TX 
Cy 100 mg/kg, 
tacrolimus or 
sirolimus
17 (15-46) 17 0 1 limited 
(skin)
0 14 haploidentical 
related donors, in 6 
patients graft rejected; 
3 matched sibling 
donors, no grafts 
rejected
Hsieh et al. 
[28], 2009
TBI 300 cGy, 
alemtuzumab
1 mg/kg, 
sirolimus
10 (16-45) 9 0 0 0 At 3 years after HSCT, 
mixed chimerism in 
all
Hsieh et al. 
[49], 2014
 
TBI 300 cGy, 
alemtuzumab
1 mg/kg, 
sirolimus
30 (16-65) 26 0 0 1
(GVHD)
At median 3.4 
years 15 patients 
discontinued 
immunosuppression 
medication
Krishnamurti 
et al. [48],
2008
BU 6.4 mg/kg 
IV or 8 mg/kg 
PO, FLU
175 mg/kg, 
ATG, 500 cGy 
of TLI, CSA, 
MMF
7 (6-16) 6 1 (Gr 2, 
skin)
1 limited 
(skin)
0 Mixed chimerism in 4
Jacobsohn et 
al. [46], 2004
BU 6.4 mg/kg 
IV, FLU 180 
mg/m2, ATG, 
CSA, MMF
1 (22) 0 1 (Gr 1) 1 extensive 1 
(GVHD)
 
Iannone et al. 
[47],
2003
TBI 200 cGy, 
FLU 150 mg/
m2, CSA or 
tacrolimus, 
MMF
6 (3-20) 0 1 (Gr 2) 0 0 Transient engraftment 
in 5 patients for  97-
441 days
ATG: Antithymocyte globulin, cGy: centigray, CSA: cyclosporine A, Cy: cyclophosphamide, FLU: fludarabine, Gr: grade, IV: intravenous, MMF: mycophenolate 
mofetil, MTX: methotrexate, PO: per os, SCD: sickle cell disease, TBI: total body irradiation, TLI: total lymphoid irradiation, GVHD: graft-versus-host disease,  
HSCT: hematopoietic stem cell transplantation.
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In general, small proportions of engrafted donor red cells 
seem to be sufficient for clinical control of the disease in SCD 
patients [50]. Hsieh et al. reported that they achieved permanent 
engraftment in 26/30 patients and that no patients developed 
acute GVHD (aGVHD) or cGVHD with a nonmyeloablative-
conditioning regimen using alemtuzumab (Campath) and 
low-dose total-body irradiation (TBI). The mean donor T-cell 
level was 48% and the myeloid chimerism level was 86%. 
Fifteen engrafted patients discontinued immunosuppression 
medication with continued stable donor chimerism and no 
GVHD [49]. In this study, sirolimus (rapamycin) was selected 
as the immunosuppressive agent instead of cyclosporine. 
Differently from calcineurin inhibitors, sirolimus does not 
block T-cell activation, but it inhibits T-cell proliferation. 
The activated but nonproliferated T cells become anergic, 
resulting in T-cell tolerance. Sirolimus accelerates the 
differentiation of regulatory and helper T cells and this plays a 
key role in immune tolerance development. Additionally, the 
renal toxicity of sirolimus is less than that of cyclosporine. 
Luznik et al. showed that high-dose cyclophosphamide given 
in the early posttransplantation period could lead to immune 
tolerance by killing proliferative alloreactive T cells and 
preserving nonreactive T cells. High-dose cyclophosphamide 
is highly toxic to lymphocytes, but hematopoietic stem cells 
are not affected as they are rich in the aldehyde dehydrogenase 
enzyme that metabolizes the drug. Posttransplantation high-
dose cyclophosphamide deletes alloreactive T cells without 
affecting nonreactive T cells or hematopoietic stem cells, 
thereby reducing the risk of GVHD and enabling immune 
reconstitution [38]. Bolanos-Meade et al. achieved bone 
marrow transplantation in adult SCD patients with 14 
haploidentical relative donors and 3 matched sibling donors 
using a nonmyeloablative-conditioning regimen containing 
cyclophosphamide, ATG, fludarabine, TBI (200 cGy), and 
posttransplantation high-dose cyclophosphamide [36].
Proposed solution: Novel regimens to reduce GVHD risk 
and toxicity and prevent graft loss in SCD patients need to be 
developed. Such regimens may include the following:
ATG-Fresenius: The drug used in preliminary studies is 
referred to as ATG-thymoglobulin (rabbit) in the literature 
and its half-life is about 12 h. ATG-Fresenius (rabbit) has a 
longer half-life (4-10 days) and would provide a significant 
advantage for preventing graft loss and GVHD.
Busulfex (busulfan): Added to conditioning regimens at 
microablative doses considering organ injuries. It would open 
spaces in the bone marrow and help to prevent graft loss.
Treosulfan: Used safely and effectively instead of busulfan 
in nonmyeloablative regimens in thalassemia patients due to 
its lower toxicity [51]. However, there is no experience of its 
use in SCD.
Fludarabine: Used in nonmyeloablative-conditioning 
regimens in pediatric and adult SCD patients with tissue 
injuries [52].
Sirolimus: An immunosuppressive agent with an 
immunotolerogenic effect [53]. It is superior to cyclosporine 
for providing engraftment without GVHD and reducing 
posterior reversible encephalopathy syndrome incidence 
[28,49].
Posttransplantation cyclophosphamide: Posttransplantation 
high-dose cyclophosphamide, which is successfully used in 
haploidentical transplantations, should be included in the 
conditioning regimen. This approach was first described by 
Luznik et al. Interestingly, while cyclophosphamide given 
in the early posttransplantation period kills proliferative 
alloreactive T cells, it preserves resting nonreactive T cells. 
Thus, immune tolerance occurs, GVHD is prevented, T-cell 
reconstitution is achieved in a short time, and the infection 
risk decreases [36]. As positive results were obtained in 
transplantations with HLA-unmatched donors in previous 
studies, it would also enable haploidentical transplantations. 
The donor pool would be larger and patients without fully 
matched donors would have a chance of being cured.
Pretransplantation immune suppression: Administration 
of 2 cycles of dexamethasone (25 mg/m2/day for 5 days) to 
suppress T-cell functions, facilitate engraftment, decrease 
the GVHD risk, and facilitate the control of disease-related 
inflammation [54].
Peri- and posttransplantation low-dose steroid 
administration: Is included in haploidentical protocols and 
would decrease potential immunologic events (GVHD, graft 
loss, etc.) by suppressing inflammatory cytokines (TNF-α, IL-
2, and IL-6) in SCD, which is an inflammatory disease [55].
An adult patient who underwent peripheral stem cell 
transplantation with a conditioning regimen designed in 
accordance with the principles recommended above showed 
no transplant-related adverse events during 20 months 
following transplantation [56]. Another SCD patient who 
underwent peripheral stem cell transplantation reached day 
10 months following transplantation and is being followed 
with no complications (unpublished data).
Late Complications
Problem: Development of late complications. 
Patients with SCD are susceptible to common transplant-
related late complications such as infertility, primary 
gonadal failure, primary hypothyroidism, insulin-dependent 
diabetes mellitus, osteoporosis, and cGVHD. Fertility is 
affected by multifactorial causes related to the disease and 
the procedure [57]. On the other hand, the course of SCD-
related complications like stroke, pulmonary hypertension, 
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acute chest, nephropathy, and acute vascular necrosis is an 
unresolved issue for adult patients. The general prediction is 
that these complications can improve after transplantation. 
Due to the absence of available data in adult patients, we 
accessed pediatric data showing long-term hematological 
improvements after HSCT with sustained engraftment. 
These data have supported this expectation in most studies 
[58,59,60]. However, if myeloablative regimens are used, 
data show that SCD-related organ injuries deteriorate after 
transplantation over time. This was attributed to the toxic 
effect of drugs [58,59,60].
Proposed solution: Few published studies have evaluated 
infertility in patients who received a nonmyeloablative 
regimen. Therefore, semen cryopreservation or ovum/
zygote cryopreservation should be recommended before 
transplantation. Current studies indicate that other transplant-
related late complications, particularly aGVHD and cGVHD, 
are within acceptable limits in adults and can be managed by 
appropriate treatment with L-thyroxin, calcitriol, estrogen, 
zoledronic acid, etc. [50,58,59]. The use of nonmyeloablative 
reduced-intensity conditioning is mandatory for adult 
patients. In addition, it may require individualization of the 
conditioning regimens as discussed above.
Further studies are required in adults for determining 
whether reduced-intensity conditioning regimens may offer 
better outcomes after HSCT.
Conclusion
Although results of HLA-matched sibling HSCT are 
encouraging, particularly in children, there are many barriers 
to this curative treatment option. What risk of mortality and 
GVHD will families accept in the early period of this benign 
disease? In one study, only 37% of relatives of patients accepted 
a 15% mortality risk; only 13% accepted a 15% mortality risk 
and a 15% GVHD risk [60].
Only a small proportion of patients may be candidates for 
transplantation due to the difficulty to find a matched sibling 
donor, absence of financial or psychosocial support, the 
family’s not accepting HSCT or the physician’s not choosing 
HCST as a treatment option. In one study, only 44 of 315 
patients were found to have an HLA-matched sibling donor 
[61,62]. In addition, the likelihood of finding an unrelated 
fully matched donor is very low [34]. An unrelated CBT trial 
was terminated early due to high risks of rejection and GVHD 
[35]. Studies to enlarge the donor pool are required. The 
study of posttransplantation high-dose cyclophosphamide 
by Bolanos-Meade et al. is encouraging in this regard. Severe 
GVHD and immunodeficiency, which are seen in mismatched 
transplantation, were not seen in any of their patients [36].
Development of organ injuries in adult patients 
requires use of low-toxicity nonmyeloablative regimens for 
transplantation. This approach results in high rates of graft 
loss with current conditioning regimens. Although return of 
the disease is acceptable in such cases, it is one of the barriers 
that affect the success of transplantation.
Gene transfer to autologous hematopoietic stem cells 
via viral vectors and gene therapies performed via induced 
pluripotent stem cells might be possible solutions to the 
difficulties in finding a matched donor and are exciting 
treatment options [63,64].
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